Cas:12704-91-5 Grease of high temperature III manufacturer & supplier

We serve Chemical Name:Grease of high temperature III CAS:12704-91-5 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.

Grease of high temperature III

Chemical Name:Grease of high temperature III
CAS.NO:12704-91-5
Synonyms:APIEZON GREASE M;Paraffin wax
Molecular Formula:C31H64
Molecular Weight:436.84000
HS Code:

Physical and Chemical Properties:
Melting point:N/A
Boiling point:N/A
Density:N/A
Index of Refraction:
PSA:
Exact Mass:436.50100
LogP:12.33910

Material Safety Information (Applicable for Hazard Chemicals)
RIDADR:
Packing Group:


Contact us for information like APIEZON GREASE M chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,Paraffin wax physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,Paraffin wax Use and application,Paraffin wax technical grade,usp/ep/jp grade.


Related News: During analysis of the clinical trial data, the researchers realized that about a third of the participants had low levels of abnormal tau protein, which makes them not very suitable for evaluating the effects of a treatment halting the progression of tau pathology. Grease of high temperature III manufacturer ICIG is a privately owned industrial holding company focusing on mid-sized chemicals and pharmaceutical businesses. Grease of high temperature III supplier ICIG is a privately owned industrial holding company focusing on mid-sized chemicals and pharmaceutical businesses. Grease of high temperature III vendor However, compared with the 60-70% refinement rate in developed economies such as North America, Western Europe, and Japan, China is still only equivalent to the level of the United States in the 1980s. There is still a lot of room for improvement in China’s refinement rate. period. Grease of high temperature III factory During analysis of the clinical trial data, the researchers realized that about a third of the participants had low levels of abnormal tau protein, which makes them not very suitable for evaluating the effects of a treatment halting the progression of tau pathology.